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By letter of 15 June 1990 the Council consulted the European Parliament, 
pursuant to Article 100a of the EEC Treaty, on the Commission proposal for a 
Council directive on advertising of medicinal products for human use. 
At the sitting of 9 July 1990 the President of Parliament announced that he 
had referred this proposal to the Committee on the Environment, Public Health 
and Consumer Protection as the committee responsible and to the Committee on 
Economic a~d Monetary Affairs and Industrial Policy and the Committee on Legal 
Affairs and Citizens' Rights for their opinions. 
At its meeting of 17 July 1990 the Committee on the Environment, Public Health 
and Consumer Protection appointed Mrs Schleicher rapporteur. 
At its meetings of 17 October, 29 October and 18 December 1990, 31 January 
and 5 April 1991 it considered the Commission proposal and the draft report. 
At the last meeting it adopted the draft legislative resolution by 12 votes 
to 0 with 2 abstentions. 
The following took part in the vote: Collins, chairman; Schleicher, vice-
chairman and rapporteur; Amendola, Chanterie, Di Rupo, Duarte Cendan (for 
Avgerinos), Green, Caroline Jackson, Muntingh, Oomen-Ruijten, Pollack, 
Pompidou (for Fitzsimons), Valverde Lopez and Vernier. 
The opinion of the Committee on Economic and Monetary Affairs and Industrial 
Policy is attached. The Committee on Legal Affairs and Citizens' Rights 
decided on 19 September 1990 not to deliver an opinion. 
The report was tabled on 7 May 1991. 
The deadline for tabling amendments will appear on the draft agenda for the 
part-session at which the report is to be considered. 
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A 
Commission proposal for a Council directive 
on advertising of medicinal products for human use 
Commission text1 Amendments 
(Amendment No. 1) 
Third recital 
Whereas Council Directive 89/552/EEC 
of 3 October 1989 on the 
coordination of certain provisions 
laid down by law, regulation or 
administrative action in Member 
States concerning the pursuit of 
television broadcasting activities 
prohibits the television advertising 
of medicinal products which are 
avai 1 able only on medical 
prescription in the Member State 
within whose jurisdiction the 
television broadcaster is located; 
whereas this principle should be 
made of genera 1 a pp 1 i cation by 
prohibiting all advertising of 
medicinal products which are 
available only on prescription; 
Whereas Council Directive 89/552/EEC 
of 3 October 1989 on the 
coordination of certain provisions 
laid down by law, regulation or 
administrative action in Member 
States concerning the pursuit of 
television broadcasting activities 
prohibits the television advertising 
of medicinal products which are 
avai 1 able only on medical 
prescription in the Member State 
within whose jurisdiction the 
television broadcaster is located; 
whereas an exception is made for 
advertising in professional journals 
aimed specifically and exclusively 
at members of the medical 
profession; 
(Amendment No. 2) 
Fourth recital 
Whereas advertising to the genera 1 
pub 1 i c even of non-prescription 
medicinal products could affect 
public health, if it was excessive 
and ill-considered; whereas 
advertising of medicinal products to 
the general public, where it is 
permitted, ought therefore to 
satisfy certain essential criteria 
which ought to be defined; 
Whereas advertising to the general 
public even of non-prescription 
medicinal products may affect public 
health, if it does not satisfy 
certain essential criteria which 
ought to be defined; 
(Amendment No. 3) 
Fourth recital a (new) 
Whereas regulations on advertising 
must be established not only for 
medicinal products, but also for 
other products, objects, equipment 
and techniques presented as being 
good for health; 
For full· text see COM(90) 0212 final - OJ No. C 163, 4.7.1990, p. 10 
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(Amendment No. 4) 
Fifth recital 
Whereas, furthermore, distribution 
of samples free of charge to the 
general public for promotional ends 
must be prohibited; 
Whereas, furthermore, distribution 
of prescription only samples free of 
charge to the general public for 
promotional ends must be prohibited; 
(Amendment No. 5) 
Sixth recital 
Whereas the advertising of medicinal 
products to persons qualified to 
prescribe or supply them contributes 
to the information available to such 
persons; whereas, nevertheless this 
advertising should be subject to 
strict conditions and effective 
monitoring, referring in particular 
to the work achieved within the 
framework of the Council of Europe; 
Whereas scientific information is 
important in ensuring that medicinal 
products are used correctly; 
whereas it is incumbent on the 
industry to provide all the 
necessary data for the purposes of 
correct information; whereas it is 
the task of the health authorities 
to ensure that such information is 
made available, through neutral, 
objective sources and qualified 
staff, to those who are authorized 
to prescribe and dispense medicinal 
products; 
(Amendment No. 6) 
Seventh recital 
Whereas medical sales 
representatives have an important 
role in the promotion of medicinal 
products; whereas therefore certain 
obligations should be imposed upon 
them in particular the obligation to 
supply the person visited with a 
summary of product characteristics; 
Whereas medical s a l e s 
representatives have an important 
role in the advertising of medicinal 
products; whereas such information 
also serves as a means of promotion 
and medical sales representatives 
must therefore be qualified to play 
this role and comply with specific 
obligations, in particular the 
obligation to supply the person 
vi sited with a summary of all the 
product characteristics; 
(Amendment No. 7) 
Eighth recital 
Whereas persons qualified to 
prescribe medicinal products must be 
able to carry out these functions 
objectively without being influenced 
by direct or indirect financial 
inducements; 
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Whereas persons qualified to 
prescribe medicinal products must be 
able to carry out these functions 
objectively without being influenced 
by direct or indirect financial - or 
other - inducements; 
PE 146.429/fin. 
(Amendment No. 8) 
Ninth recital 
Whereas it should be possible within 
certain restrictive conditions to 
provide samples of medicinal 
products free of charge to persons 
qualified to prescribe or supply 
them so that they can familiarize 
themselves with new products and 
acquire experience in dealing with 
them; 
Whereas it should be possible within 
certain restrictive conditions to 
provide samples of medicinal 
products free of charge to persons 
qualified to prescribe or supply 
them so that they can familiarize 
themselves with new products and 
acquire experience in dealing with 
them; these free samples of 
medicinal products must, of course, 
not be sold; 
(Amendment No. 9) 
Ninth recital a (new) 
whereas the European Agency for the 
evaluation of drugs shall be 
responsible for monitoring 
scientific information concerning 
medicinal products; 
(Amendment No. 10) 
Tenth recital 
Whereas persons qualified to 
prescribe or supply medicinal 
products must have access to a 
neutral objective source of 
information about products available 
on the market; whereas it is 
nevertheless for the Member States 
to take all measures necessary to 
this end, in light of their own 
particular situation; 
Whereas persons qualified to 
prescribe or supply medicinal 
products must have access to a 
neutral objective source of 
information about products available 
on the market; 
(Amendment No. 11) 
Tenth recital a (new) 
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Whereas in certain situations Member 
States are entitled to adopt special 
stricter measures, as appropriate; 
PE 146.429/fin. 
(Amendment No. 12) 
Tenth recital b (new) 
whereas, when implementing this 
directive, Member States must ensure 
that its provisions are applied to 
all parties which may have an 
influence on prescription practices; 
(Amendment No. 13) 
Eleventh recital 
Whereas advertising of medicinal 
products should be subject to 
effective, adequate monitoring; 
whereas reference in this regard 
should be made to the monitoring 
mechanisms set up by Directive 
84/450/EEC; 
Whereas advertising of medicinal 
products should be subject to 
effective, adequate monitoring 
carried out preventively; 
(Amendment No. 14) 
Twelfth recital 
Whereas each undertaking which 
manufactures or imports medicinal 
products should set up a mechanism 
to ensure that all information 
supplied about a medicinal product 
conforms with the approved 
conditions of use, 
Whereas each undertaking which 
manufactures or imports medicinal 
products should set up a mechanism 
to ensure that all information 
supplied about a medicinal product 
corresponds to the information 
provided in the summary of the 
characteristics of the product, as 
approved by the competent 
authorities; 
(Amendment No. 15) 
Art i c 1 e 1( 1) 
This Directive concerns the 
advertising of medicinal products 
for human use in the Community. 
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This directive aims to regulate the 
advertising of medicinal products 
for human use in the Community .i!_ 
being understood that instruction 
leaflets and labelling shall be 
subject to the prov1s1ons of 
Directive ... / ... /EEC. 
PE 146.429/fin. 
{Amendment No. 16) 
Article 1{2), second indent 
-the definition of "medicinal 
product" sha 11 be that 1 aid down 
in Article 1 of Council Directive 
65/65/EEC 
the definition of 'medicinal 
product' shall be that laid down 
in Article 1 of Council Directive 
65/65/EEC; the products defined 
in Articles 1 and 2 of COM{90) 72 
final - SYN 251 on homeopathic 
medicinal products for human use 
shall also be considered as 
medicinal products within the 
meaning of this Directive, 
{Amendment No. 17) 
Article 1{2), new indent after the second indent 
any person who advertises a 
medicinal product to a health 
care professional with a view to 
promoting the prescription or 
supp 1 y of that product for 
commercial ends shall be 
considered to be a medical sales 
representative. 
{Amendment No. 18) 
Article 1{2), new indent after the second indent 
all information intended for 
doctors, pharmacies, other health 
workers and consumers, for the 
purposes of ensuring that the 
products are used correctly, 
relating to the composition of 
the medicinal products, their 
therapeutic effect, side-effects, 
warnings, instructions for use 
and the results of controlled 
clinical tests on the 
effectiveness and the immediate 
or long-term toxicity of the 
product shall be deemed to be 
'scientific information', 
{Amendment No. 19) 
Article 1{3), first indent 
- information of a commercial nature 
for health care professionals, in 
whatever form, which may promote 
the prescription or supply of 
medicinal products; 
. 
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information {four words deleted) 
for health care professionals, in 
whatever form, which may promote 
the prescription or dispensing of 
medicinal products; 
PE 146.429/fin. 
(Amendment No. 20) 
Article 1(3), new indent after the first indent 
information for the general 
public, in whatever form, which 
may promote the consumption of 
medicinal products; 
(Amendment No. 21) 
Article 1(3), third indent 
- any incitement to prescribe or 
supply medicinal products by the 
gift, offer or promise of any 
benefit or bonus, whether in money 
or in kind, including invitations 
to travel or to congresses. 
any incitement to prescribe or 
supp 1 y medic i na 1 products by the 
gift, offer or promise of any 
benefit or bonus, whether in 
money or in kind, including 
invitations to travel. 
(Amendment No. 22) 
Article 2(2) 
All parts of the advertising of a 
medicinal product must be compatible 
with the particulars 1 i sted in the 
summary of product characteristics. 
A 11 parts of the advertising of a 
medicinal product must conform to 
the particulars ... (rest unchanged) 
(Amendment No. 23) 
Article 2(3a) (new) 
Pending the setting up, under 
Council Regulation (EEC) No .... , of 
a European Community body authorized 
to provide information for health 
care professionals, Member States 
shall ensure that persons authorized 
to prescribe or supply medicinal 
products shall have access to 
information from various sources on 
medicinal products available on the 
market. 
(Amendment No. 24) 
Article 3(1), first indent 
- medicinal products which contain 
psychotropic or narcotic 
substances, within the meaning of 
the international conventions, 
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medicinal products which contain 
psychotropic or narcotic 
substances, within the meaning of 
Schedules 1 and 2 of the United 
Nations Single Convention on 
Narcotic Drugs. 
PE 146.429/fin. 
(Amendment No. 25) 
Article 3(1), new indents after first indent 
medicinal products and products 
which are habit-forming and/or 
addictive, 
any performance-enhancing drug or 
product, as defined by the 
Counc i 1 of Europe and the 
International Olympic Committee, 
(Amendment No. 26) 
Article 3(2) 
Member States shall prohibit the 
mention in advertising to the 
genera 1 pub 1 i c of therapeutic 
indications for which self-
medication is not suitable, in 
particular: 
Member States shall prohibit the 
mention in advertising to the 
general public of therapeutic 
indications for which self-
medication is not suitable, 
- tuberculosis Delete 
- sexually transmitted diseases 
- other serious infectious diseases 
- cancer 
- chronic insomnia 
- diabetes and other metabolic 
illnesses. 
Member States shall be responsible 
for health education campaigns, 
targeted at the general public, on 
the correct use of medicinal 
products, with particular reference 
to over-the-counter drugs and those 
which may lead to abuse or which may 
become habit-forming. 
For the organization of such 
campaigns, Member States shall 
collaborate with the Agency referred 
to in Regulation (EEC) No ..... and 
with consumer associations. 
(Amendment No. 27) 
Article 3(3) 
The prohibition referred to 
paragraph 1 shall not a pp 1 y 
vaccination campaigns approved 
the competent authorities of 
Member States. 
DOC_EN\RR\109301 
in The prohibition referred to in 
to paragraph 1 sha 11 not a pp 1 y to 
by vaccination or public health 
the campaigns run or approved by the 
competent authorities of the Member 
States or to research-related 
campaigns. 
- 10 - PE 146.429/fin. 
(Amendment No. 28) 
Article 3(5) 
Member States shall 
free distribution 
products to the 
promotional purposes. 
prohibit the 
of medicinal 
public for 
Member States shall prohibit the 
free distribution of prescription-
~ medicinal products and gifts 
and bonuses to the public for 
promotional purposes. 
(Amendment No. 29) 
Article 4(a) 
a) be set out in such a fashion that 
it is cl ear that the message is 
an advertisement, and that the 
product is clearly identified as 
a medicinal product, 
a) be set out in such a fashion that 
it is cl ear that the message is 
an advertisement, and that the 
product is clearly presented as a 
medicinal product; 
(Amendment No. 30) 
Article 4(b), second indent 
the information necessary for 
correct usage of the medicinal 
product, such as indications for 
use and special precautions, or, 
failing this, an express 
invitation to read the package 
leaflet carefully. 
the information necessary for 
correct usage of the medicinal 
product, such as indications for 
use, special precautions and 
possible side effects. 
(Amendment No. 31) 
DOC EN\RR\109301 
Article 4(b), second indent a (new) 
all contra-indications, the main 
side effects or undesirable 
effects, appropriate precautions 
regarding its use, any 
interactions with other products 
and any other special warning; 
(Amendment No. 32) 
Article 4(b), second indent b (new) 
- 11 -
an express invitation to read the 
label and the package leaflet 
carefully. 
PE 146.429/fin. 
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(Amendment No. 33) 
Article 4(b), second indent c (new) 
the warning 'any medicinal 
product can be dangerous if used 
incorrectly consult your doctor'. 
(Amendment No. 34) 
Article 4(b), second indent d (new) 
the recommendation that a doctor 
or pharmacist be consulted. 
(Amendment No. 35) 
Article 4(b), second indent e (new) 
the pharmacology of the medicinal 
product, 
(Amendment No. 36) 
Article 4(la) (new) 
During any television or cinema 
advertisement for a medicinal 
product, a box shall be superimposed 
on the screen containing the 
references, warnings and contra-
indications as well as an express 
i nvi tat ion to read the package 
leaflet carefully. At the end of 
the advertisement, there wi 11 be a 
voice-over reading out the 
indication provided for in 
Article 3(1), third indent (new). 
(Amendment No. 37) 
Article 4(lb) (new) 
- 12 -
At least 20% of all advertising 
space for a medicinal product shall 
be reserved for warnings, references 
and contra-indications. 
Furthermore, the advertisement must 
be clearly identifiable and include 
the following indication: 'This is 
an advertisement'. 
PE 146.429/fin. 
(Amendment No. 38) 
Article 5 b) 
b) suggests erroneously that the 
effects of taking the medicine 
are guaranteed, or are better 
than another treatment; 
b) suggests (one word deleted) that 
the effects of taking the 
medicine are guaranteed, or are 
better than the effects of 
another treatment; 
(Amendment No. 39} 
Article 5 c) 
c) suggests that the normal good 
health of the subject can be 
enhanced by taking the medicine, 
or that it could be affected by 
not taking the medicine; 
c) Suggests that the normal good 
health of the subject (ten words 
deleted} could be affected by not 
taking the medicine; 
(Amendment No. 40) 
Article 5 ea} (new) 
ea mentions symptoms of illnesses 
for which the medicinal product 
is recommended; 
(Amendment No. 41) 
Article 5 d) 
d) is directed solely or mainly at 
children; 
d) is directed solely or mainly at 
children or at young people aged 
under 18; 
(Amendment No. 42) 
Article 5 da) (new) 
da plays on people's distress or on 
the emotion a 1 nature of the 
advertisement; 
(Amendment No. 43) 
Article 5 e) 
e) refers to a recommendation by e) refers to a recommendation by 
scientists, health professionals 
or any other persons who, because 
they are well-known, are likely 
to encourage consumption of the 
medicinal product in question; 
scientists or health 
professionals; 
DOC_EN\RR\109301 
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(Amendment No. 44) 
Article 5 ea) (new) 
ea uses pictures showing health 
care profession a 1 s wearing their 
working uniforms; 
(Amendment No. 45) 
Article 6(1), first sentence 
Any advertising of 
product to persons 
prescribe or supply 
shall include: 
a medicinal 
qualified to 
such products 
Any advertising of a medicinal 
product to persons qualified to 
prescribe or supply or dispense such 
products shall include: 
(Amendment No. 46) 
Article 6(1), third indent 
the reta i 1 price of the various 
presentations, 
deleted 
(Amendment No. 47) 
Article 6(1) fourth indent 
if appropriate, conditions of 
coverage by the soc i a 1 security 
systems. 
deleted 
(Amendment no. 48) 
Article 6(1a) (new) 
Persons qualified ~o prescribe or 
dispense medicinal products must be 
given information on the final sales 
price of each of the various 
presentations and on the conditions 
of coverage by the soc i a 1 security 
systems, in a way which conforms to 
national requirements. 
(Amendment No. 49) 
Article 6(2) 
The advertising of a medicinal 
product to persons qualified to 
prescribe or supply such products 
may, notwithstanding paragraph 1 
include only the name of the 
medicinal product, if its sole 
object is to recall to the latter. 
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The advertising of a medicinal 
product to persons qualified to 
prescribe, supply or dispense such 
products may, notwithstanding 
paragraph 1 include only the name of 
the medicinal product, if its sole 
object is to recall to the latter. 
PE---146. 429/fi n. 
(Amendment No. 50) 
Article 7(1) 
Any documentation relating to a 
medicinal product which is 
transmitted as part of the promotion 
of that product to persons qualified 
to prescribe or supply it shall 
include as a minimum the particulars 
listed in Article 6(1). 
Any documentation relating to a 
medicinal product which is 
transmitted as part of the 
advertising of that product to 
persons qualified to prescribe or 
supp 1 y it sha 11 refer to the data 
sheets drawn up by the Agency 
referred to in Regulation (EEC) No. 
(Amendment No. 51) 
Article 7(2) 
All the information contained in the 
documentation referred to in 
paragraph 1 sha 11 be accurate, up-
to-date, verifiable and sufficiently 
complete to enable the recipient to 
form his or her own opinion of the 
therapeutic value of the medicinal 
product concerned. 
All the information contained in the 
documentation referred to in 
paragraph 1 sha 11 be accurate, up-
to-date, verifiable and (one word 
deleted) complete (rest deleted). 
(Amendment No. 52) 
Article 7(2a) (new) 
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A European Data Bank on medicinal 
products, provided for in Council 
Regulation (EEC) No. of , to 
be managed jointly by the Commission 
and the representatives of the 
manufacturers and importers 
concerned, shall centralize all 
information on all the medicinal 
products marketed in the European 
C o mm u n i t y . A 1 1 he a 1 t h care 
professionals in the Community may 
have direct access to the data bank 
by telephone or computer 24 hours a 
day. Each producer or importer of 
pharmaceutical products shall pay 
0.2% of its turnover in EC territory 
to the European Data Bank. 
PE 146.429/fin. 
(Amendment No. 53) 
Article 7(2b) (new) 
Within one year of being set up, the 
Drugs Agency referred to in 
Regulation (EEC) No. shall draw 
up regulations for correct 
information on pharmaceutical 
products 1 i sted according to 
therapeutic categories. 
Within the same period, the Member 
States sha 11 forward to the 
Commission the names of medical 
sales representatives entered in 
national registers. 
(Amendment No. 54) 
Article 8(2) 
During each visit, medical sales 
representatives shall provide the 
persons visited with the summaries 
of product characteristics in 
respect of each medicinal product 
which they present. 
During each visit, medical sales 
representatives shall provide health 
care professionals with the 
summaries of product characteristics 
in respect of each medicinal product 
which they present. 
(·Amendment No. 55) 
Article 8(3) 
Medical sales representatives shall 
transmit to the scientific service 
referred to in Article 12(1), any 
information about the use of the 
medicinal products they promote, 
especially about adverse reactions, 
that is reported to them by the 
persons they visit. 
Medical sales representatives shall 
transmit to the scientific service 
referred to in Article 12(1), any 
information about the use of the 
medicinal products they advertise 
especi a 11 y about adverse reactions, 
that is reported to them by the 
persons they visit. 
(Amendment No. 56) 
Art i c 1 e 9 ( 1) 
In the course of promoting medicinal 
products to persons qualified to 
prescribe them, it shall be 
prohibited to give, proffer or 
promise to such persons, directly 
or indirectly, any gifts, pecuniary 
advantages or benefits in kind, with 
the exception of objects of an 
insignificant intrinsic value. 
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In the course of advertising 
medicinal products to persons 
qua 1 ifi ed to prescribe them, it 
shall be prohibited to give, proffer 
or promise to such persons, directly 
or indirectly, any gifts, pecuniary 
advantages or benefits in kind. 
(rest deleted) 
PE 146.429/fin. 
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1. The provisions of Article 9 shall 
not prevent undertakings which 
produce or import medicinal 
products from organizing 
congresses intended solely for 
the further scientific training 
of health care professionals. 
2. In this case, the hospitality 
extended to participants must be 
subordinate to the main 
scientific objective of the event 
during which it is provided. 
Such hospitality shall be 
extended only to health care 
professionals. 
3. The undertakings referred to in 
paragraph 1 shall notify Member 
States of any congress which they 
help to organize. They shall 
provide the following information 
at least 60 days before the start 
of the congress: 
budget details, 
the identity of the sponsor 
the aim, duration, programme 
and location of the congress. 
Member States shall make such 
information available to the 
Commission and to any other body 
designated by the Commission for 
this purpose. 
4. Within two years of the adoption 
of this directive the Commission 
shall draw up a code of practice 
regarding the financing by 
ph armaceut i ea 1 companies of 
congresses or other education a 1 
or information activities aimed 
at the medical profession. 
5. The Commission shall submit a 
report on the application of this 
article to Parliament and the 
Counci 1 by 31 December 1996. 
Where appropriate, it shall 
submit suitable amendments in the 
light of such information. 
PE 146.429/fin. 
(Amendment No. 58) 
Article 10, first sentence 
Where medicinal products are being 
promoted to persons qualified to 
prescribe or supply them, free 
samples shall be provided to such 
persons only on the following 
conditions: 
Where medicinal products are being 
advertised to persons qua 1 i fi ed to 
prescribe or supply or dispose them, 
free samples shall be provided to 
such persons only on the following 
conditions: 
(Amendment No. 59) 
Article 10 a) 
a) two samples at the most may be 
provided every year to any person 
qualified to prescribe or to 
supply medicinal products; 
a) samples of medicinal products 
may be provided only where such 
products have been on the market 
for not more than three years. 
However, subject to the 
provisions of (f), newly-
qualified doctors may request 
samples of any medicinal 
products, for a period of three 
years, irrespective of the date 
on whi eh such products received 
market authorization; 
(Amendment No. 60) 
Article 10 b) 
b) any supply of samples must be in 
response to a written request, 
signed and dated, of the 
recipient; 
b) after the period referred to in 
Article 10(a), samples may be 
authorized, following a written 
request, signed and dated, from 
the recipient; 
(Amendment No. 61) 
Article 10 c) 
c) the samples shall be identical to 
the smallest presentation on the 
market; 
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c) the content of the samples must 
be identical to that of the 
sma 11 est marketed pack and must 
make it possible to administer at 
least one initial dose of 
treatment. 
• 
PE 146.429/fin. 
(Amendment No. 62) 
Article 10 d) 
d) the samples shall be marked "free 
medical sample - not for resale" 
or with another 1 egend of 
analogous meaning; 
d) the samples shall be marked, 
clearly and indelibly, 'free 
medical sample - not for resale' 
or with another 1 egend of 
analogous meaning; 
(Amendment No. 63) 
Article 10 e) 
e) the samples shall be accompanied 
by a copy of the summary of 
product characteristics. 
e) The samples shall be supplied 
together with a copy of the 
summary of product 
characteristics, in addition to 
the leaflet intended for patients 
which is usually included in the 
pack. They shall be sent in a 
specific consignment by the 
company responsible for marketing 
the product. 
(Amendment No. 64) 
Article 11(2) 
2. Under the legal provisions 
referred to in paragraph 1, 
Member States shall confer upon 
the courts or administrative 
authorities powers enabling them: 
to order the discontinuance, 
correction or withdrawal of any 
advertisement inconsistent with 
this Directive, 
require either the publication of 
a corrigendum, or the publication 
in whole or in part and in a form 
which it shall deem adequate, of 
the decision ordering the 
discontinuance of an 
advertisement. 
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2. (First 9 words deleted) Member 
States shall confer upon the courts 
or the administrative authority 
referred to in paragraph 1 powers 
enabling them, through emergency 
procedures: 
(first indent unchanged) 
to require either the publication 
of a corrigendum, or the 
publication in whole or in part 
and in a form which it shall deem 
ad e q u at e , of t h.e de c i s i on 
ordering the discontinuance of an 
advertisement; in the event of 
serious infringements, such 
corrigendum or publication may 
have the same features 
(advertising medium, duration, 
size, circulation or number of 
publications, etc.} as the 
advertisement in question. 
PE 146.429/fin. 
(Amendment No. 65) 
Art i c 1 e 11 ( 3) 
3. Under the legal provisions 
referred to in paragraph 1, 
Member States shall ensure that 
any decision taken in accordance 
with paragraph 2 shall state in 
detail the reasons on which it is 
based and shall be communicated 
in writing to the person 
concerned, mentioning the 
remedies available at law and the 
time 1 i m it all owed for the 
exercise of such remedies. 
3. (First nine words deleted) Member 
States shall ensure that any 
decision taken in accordance with 
paragraphs 1 and 2 shall state in 
detail ... (rest unchanged) 
(Amendment No. 66) 
Article 12(1) 
The person responsible for marketing 
shall establish within his 
undertaking a scientific service in 
charge of information about the 
medicinal products which he places 
on the market. 
The person who has received market 
authorization or the person 
responsible for marketing must have 
recourse at the very least to a 
scientific board for medical 
information, headed by a health care 
professional, responsible ~or 
advertising the medicinal products 
which he placed on the market. 
(Amendment No. 67) 
Article 12(2), first sentence 
2. The person res pons i bl e 
marketing shall: 
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(Amendment No. 68) 
Article 13(1) 
1. Where the provisions of the 
Directive have not been observed, 
and a warning notice served on 
the party concerned has remained 
without effect, the competent 
authorities of a Member State may 
suspend the authorization to 
market the medicinal product 
concerned, without prejudice to 
any other sanction whi eh may be 
applied under national law. 
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1. Where the provisions of the 
Directive have not been observed, 
and a warning notice served on the 
party concerned has remained without 
effect within the deadline set by 
that notice, the competent 
authorities of a Member State shall 
decide on penalties pending a 
sufficient deterrent, and, in the 
most serious cases, may even go so 
far as to suspend the authorization 
to market the medicinal product 
concerned. 
Member States sha 11 introduce into 
their national legislation the 
provisions necessary for the 
application of this article. 
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DRAFT LEGISLATIVE RESOLUTION 
(Cooperation procedure: first reading) 
embodying the opinion of the European Parliament on the Commission proposal 
for a Council directive on advertising of medicinal products for human use 
The European Parliament, 
having regard to the Commission proposal to the Council (COM(90) 0212 
final - SYN 273) 2 , 
having been consulted by the Council pursuant to Article 100a of the EEC 
Treaty (C3-0185/90), 
having regard to the report of the Committee on the Environment, Public 
Health and Consumer Protection and the opinion of the Committee on Economic 
and Monetary Affairs and Industrial Policy (A3-0127/91), 
1. Approves the Commission proposal subject to Parliament's amendments and in 
accordance with the vote thereon; 
2. Calls on the Commission to amend its proposal accordingly, pursuant to 
Article 149(3) of the EC Treaty; 
3. Calls on the Council to incorporate Parliament's amendments in the common 
position that it adopts in accordance with Article 149(2)(a) of the EEC 
Treaty; 
4. Instructs its President to forward this opinion to the Council and 
Commission. 
2 OJ No. C 163, 4.7.1990, p. 10 
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B 
EXPLANATORY STATEMENT 
1. European legislation on advertising 
As 1 ong ago as the 1 ate 1950s, i.e. 1 ong before the existence of the First 
Community Action Programme on Consumers of 14 April 1975, the Commission 
deemed there was a need for European legislation on 'unfair competition'. The 
Commission's ponderous approach to the subject can be seen in the fact that 
it took almost ·20 years to present an initial proposal for a directive on 
misleading and unfair advertising (COM(77) 724 final of 28 February 1978). 
This proposal then spent another six years being pulled to pieces and further 
watered down at various meetings of the Council. Finally, agreement was 
reached in 1984 but only on misleading advertising. Despite the fact that 
both the Commission and the Council have repeatedly recognized the need for 
one, the Commission has still not produced a new proposal concerning unfair 
advertising. Nor has it yet produced a draft proposal on comparative 
advertising which is also deemed necessary and which was announced several 
years ago. 
The European internal market will be completed in just on two years time. 
Industry has already responded by expanding Europe-wi de. Advertising law is 
now hobbling along some three decades behind. Persons intending to advertise 
in other EC countries need to know and respect the law in force in such 
countries. This can cause considerable problems. Not only has advertising 
law developed on different lines in the Member States but it is also, for 
linguistic reasons, not readily accessible. Framework legislation on 
advertising needs to be developed as soon as •possible, not only to protect 
consumers but also in the interests of industry. 
The development of the internal market and rapid technological changes in 
communications, in particular the audiovisual media, resulted in the adoption 
of the 'television directive' in 1989. This directive and the directive on 
misleading advertising contain legislation which is applicable directly or 
indirectly to advertising for pharmaceutical products. 
In contrast to these two examples of European framework legislation - which 
urgently need to be expanded to include unfair and comparative advertising -
the Commission is increasingly tending to propose detailed and restrictive 
legislation on advertising for specific products. 
The first attempt was the proposal for a directive on the approximation of 
the laws of the Member States relating to claims made in the labelling, 
presentation and advertising of foodstuffs for sale to the ultimate consumer 
(Doe. 1-224/81 COM(81) 159 final). Parliament rejected this proposal 
(Doe. 1-1207/82, ·pE 79.064/fin., 7.2.1983). Besides specific difficulties 
concerning the areas to be covered by the legislation, even in 1983 Parliament 
objected to the fact that various prov1s1ons covered the same areas as 
individual and framework legislation without being formulated in exactly the 
same terms. Parliament objected to individual directives being proposed 
without taking into account the underlying issues. It was also concerned 
about unnecessary and confusing duplication. It called on the Commission to 
ensure that new proposals were in line with existing proposals. 
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Despite these objections, the Commission has now submitted two further 
detailed items of legislation concerning advertising: 
the directive on advertising tobacco products (Parliament's opinion on 
first reading on 14.3.1990) 
and the present proposal for a directive on advertising of medicinal 
products for human use. 
On the whole, the Commission's proposal for a directive on advertising 
medicinal products is well-balanced and it represents an appropriate legal 
framework for the advertising of such products in the Community. It is 
regrettable, however, that the Commission is once again proposing a detailed 
directive for a specific group of products without first having proposed 
framework directives for unfair and comparative advertising. If there were 
comprehensive legislation on these two areas in the form of a European 
framework directive, there would be no need for a number of detailed 
proposals, including some of those in the present text. In fact, the 
directive on misleading advertising (in force since 1984) and the 1989 
dire et i ve on television advertising a 1 ready cover a number of points in the 
Commission's proposal whi eh are therefore unnecessary. European l egi slat ion 
should always be aimed at laying down appropriate and unambiguous basic 
conditions embracing uniform criteria for assessment. 
It is also questionable whether differences in legislation on advertising of 
medicinal products really do constitute a barrier to trade. The example 
quoted by the Commission (judgment of 6 March 1990, Case GB-INNO-BM ./. CCL) 
is specifically concerned with mail shots and not with differences in the 
substance of advertising. This matter - the free distribution of printed 
matter- is generally covered by the Helsinki and Vienna Agreements and by 
international postal agreements. 
Given the considerable interest in medicinal products and advertising of them, 
it is understandable for political reasons, however, that the Commission has 
drawn up a proposal for a directive. 
II. Contents of the proposal for a directive 
There are already statutory and voluntary restrictions in all Member States on 
advertising to the general public for non-prescription medical products 
(including those sold only by pharmacists). The intention is to harmonize the 
different national schemes in such a way that the properties of the medicinal 
products are presented objectively in advertising. The proposal specifies 
what information has to be provided as a minimum requirement in advertising of 
medicinal products to the general public. Certain advertising claims are 
banned. 
All Member States already prohibit the advertising of prescription-only 
medicinal products. The Commission proposal incorporates this prohibition. 
With the exception of specialist literature, the 'advertising' of 
prescription-only products is permitted only in the form of direct visits to 
health professionals. The Commission's proposal therefore includes this area, 
too. Yet it is precisely in this area that it is difficult to draw a 
d i st i net ion between 'advertising' and essent i a 1 forms of 'information' . The 
Commission's proposal also regulates the supervision of advertising in the two 
areas and provides for penalties. 
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Ill. Evaluation of the proposal for a directive 
1. The role of medicinal products in health care 
Medicinal products play a key role in all health care systems in the countries 
of the European Community. Approximately 80% of all illnesses are alleviated 
or treated through medicaments. Cost-benefit analyses have clearly shown that 
for many illnesses medicinal products are by far the cheapest and, in very 
many instances, the only form of treatment. They are therefore important not 
only for medical reasons but also on cost grounds. 
Conditions for the advertising of medicinal products 
By virtue of EC directives dating from 1965 (65/65/EEC) and 1975 (75/318/EEC 
and 75/319/EEC), which have been continuously updated since then, medicinal 
products are subject to a strict approval procedure in the countries of the 
European Community. They are tested for effectiveness, harmlessness and 
quality. If these criteria are not fulfilled the product is not authorized, 
or in some cases authorization can be revoked by the competent body. 
The free movement of medicinal products will be facilitated by the future EC 
authorization procedure, the draft of which has been submitted by the 
Commission (COM(90) 283 final}. The product claims approved by the 
authorization procedure will be the basis for the advertising claims and for 
the information supplied to specialists. 
In contrast to the Commission proposal, the Member States' pharmaceuticals 
legislation makes a distinction between 'information for specialists' and 
'product advertising as such'. The annex contains a survey of national 
regulations currently in force on information for specialists. 
2. Advertising of medicinal products to the general public 
Advertising claims 
The basic principle is that advertising is permitted only for non-prescription 
medicinal products. Advertising is intended to make the product and its areas 
of application known. For manufacturers it is an important means of drawing 
attention to tested and authorized products. All claims of substance in the 
advertising are based on the authorization certificate and/or registration by 
the competent authorization body; i.e. there is a neutral basis. Advertising 
to the general public is also intended to provide information on specific 
preventive effects of the product and to indicate ways of overcoming mild 
feelings of ill-health. This information therefore helps reduce public 
spending on sickness insurance systems. All the countries of the Community 
are undertaking efforts to redistribute social insurance resources with a view 
to targeting the central measures and reducing the financial burden of trivial 
illnesses. In this context a ban on the advertising of non-prescription 
reimbursable products· will be counter-productive, quite apart from the fact 
that, as the Commission itself says, this 'grey area' accounts for only a very 
small proportion of advertised products and it varies from country to country. 
As long as there are no plans for harmonization of European social insurance 
systems, a European ban on the advertising of non-prescription reimbursabl e 
products would create new inequalities. 
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Restricting advertising statements for certain illnesses, as proposed by the 
Commission, reflects national practices. 
Furthermore, it is irresponsible if advertising is addressed specifically or 
exclusively to children and young persons. Further restrictions are needed 
here. 
There are various sources of specialist information on medicinal products and 
these are an important source of product safety. People are becoming more 
health-conscious; hence their interest in, and de si re for, better 
information. Responsible advertising should supply this information. 
However, advertising of medicinal products cannot include every single detail 
if the information is to remain comprehensible. Nevertheless, a majority of 
the Committee felt it would be sensible to include in advertising to the 
general public not only the name of the medicinal product together with the 
usual general description, but also instructions on use, precautionary 
measures, contra-indications, the main side-effects and possible interactions 
with other products and any special information. Advertising to the general 
public, it was felt, should also include a specific invitation to read the 
label and package information. A majority of members of the Environment 
Committee also felt it necessary to point out that every form of advertising 
should include the following statement: 'Any medicinal product can be 
dangerous if misused. Consult your doctor or chemist'. 
The rapporteur would have considered it enough to include in the advertising 
to the general public of prescription-only products not only the name of the 
product and its application but also a compulsory text drawing the attention 
of consumers to the packaging leaflet and/the labelling. This is not intended 
as a means of withholding information, but as a means of drawing the 
consumer's attention to comprehensive sources of information on the product. 
Pharmacists are available to advise consumers on purchasing products and they 
can provide information on them. (In Germany, pharmacists are by far the 
commonest source of information for consumers, fo 11 owed by doctors and - a 
long way behind- the media or other sources). 
Package leaflets 
The main source of consumer information for self-administered products are the 
package leaflet and the labelling. Another Commission proposal {COM{89) 207 
final) proposes that this be standardized Community-wide and presented in a 
form which the consumer can easily understand. 
The important point is that the package leaflet, as a source of information, 
should be checked and approved by the approval authorities to ensure that the 
information is neutral and scientifically sound. In many countries there are 
reference works for patients which provide clear and easily understood 
information on non-prescription products on the basis of the text contained in 
the package 1 eafl et. A reference to the package 1 eafl et must therefore be 
made a standard feature of all forms of advertising. 
Forms of advertising 
Nine Member States permits advertising of medicinal products in all media. In 
Denmark there is a general ban on audiovisual media {which also, of course, 
includes non-prescription products). In Greece there is an absolute ban on 
pharmaceutical advertising but the importance of this should not be 
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exaggerated because there are only two substances (as pi ri n and paracetamol) 
which can be administered without a prescription. Belgium is the only Member 
State with a specific ban on the advertising of medicinal products on TV and 
in the radio. However, in a press release of 27 June 1990 the Deputy Minister 
of Public Health stated that, in the light of European developments, the 
Belgian Government was considering removing this restriction which is peculiar 
to Belgium. 
In Greece, too, there is considerable discussion on making an 
number of substances prescription-free and, connected with 
introduction of advertising to the general public. 
appreciable 
this, the 
This means that advertising to the general public in all media for non-
prescription products is on the way to being accepted in all countries of the 
Community. Si nee advertising is an important feature of 1 i bera 1 economic 
systems, this development is not surprising in view of the future Common 
Market. A majority of members of the Environment Committee felt there was a 
need to add two new paragraphs to Article 4 to cover regulations on 
advertising on television or in cinemas and on warnings, references and 
contra-indications. 
To summarize, a balanced critical attitude is the most appropriate approach. 
3. Information on medicinal products 
Medicinal products are a particular type of goods. In contrast to many 
consumer goods, the correct application of a medicinal product presupposes 
comprehensive information on the healing properties and the potential risks. 
This is particularly true of what is in general the complex use of such 
products for therapeutic purposes. With new products the manufacturer's 
information, the substance of wh i eh is based on the authorization procedure 
for the product, is of particular importance. In all the countries of Europe 
there are reference works for specialists based on the product properties as a 
whole; they constitute an independent source of information (in Germany the 
reference work is the 'red list' which is updated annually and made available 
free of charge to health professionals). Besides this standard information, 
pharmaceutical firms normally provide health professionals with additional, 
detailed information on request and free of charge. 
The information to be provided to health professionals (Chapter III) is 
exclusively the responsibility of the manufacturer. The retail price-
setting and sickness insurance schemes' conditions of coverage will continue 
to differ widely in accordance with national practice. In the Community, 
reimbursement systems are state-run, semi -state-run, private, company-based 
and profession-wide. In some countries the retail prices of certain groups of 
medicinal products are determined by pharmacists. 
The minority felt that, given the considerable system-related differences 
between the individual countries, it was not possible to impose on 
manufacturers a set of European 'advertising rules' covering information on 
the retail price of medicinal products and the sickness insurance schemes' 
conditions of coverage. However, the majority followed the Commission's 
approach and made it more explicit. 'Persons qualified to prescribe or 
dispense medicinal products must be given information on the final sales price 
of each of the various presentations and on the conditions of coverage by the 
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social security systems, in a way which conforms to national requirements.' 
(Amendment No. 48). 
At the initiative of the Commission a European database for medicinal 
products is currently being developed which will also include a summary of the 
product characteristics of each product. Healt~ professionals will be able to 
see where there may be possible differences in scientific assessment by the 
national authorization bodies. The future system of European registration of 
medicinal products could eliminate and standardize any existing differences. 
This European database is an additional, independent source of information 
for health professionals. A majority of the Environment Committee supported 
including an explicit reference to the European database for medicinal 
products, together with information on how it operates and how it is funded 
(Amendment No. 52). 
A majority also favoured including a reference to the European Agency for the 
evaluation of drugs, the subject of a Commission proposal (COM(90) 283 final), 
and its task of monitoring scientific information concerning medicinal 
products (Amendment No. 9). The rapporteur believes this is premature in that 
the details of the Agency's tasks and structure are still the subject of 
political discussion. 
The advertising and sales promotion of medicinal products to health 
professionals is principally the task of medical sales representatives who 
therefore play an important part in disseminating medical information. 
Although the Committee was unable to go as far as the rapporteur - who called 
for additional, scientifically trained medical sales representatives to 
provide information to health professionals - the Committee wants them to be 
'qualified to play (their) role and comply with specific obligations' 
(Amendment No. 6). 
The whole issue of information on side-effects and the risks of medicinal 
products is covered in a detailed chapter in the draft 'authorization 
directive for m~dicinal products' and, in the rapporteur's opinion, ought not 
to be covered in the 'advertising directive' in a few lines in the chapter on 
'advertising to health professionals'. It would be more appropriate to make 
reference to the more detailed rules concerned in the authorization directive. 
This was not the view taken by the majority. 
Samples of medicinal products have traditionally been an important means of 
providing information on a new product. However, 1 i m it i ng the number of 
samples would seem appropriate on economic grounds and for reasons of health 
policy. A majority of members of the Committee were of the opinion that the 
Directive should specify that samples of medicinal products should be supplied 
only if no more than three years had elapsed since the actual date of 
marketing the product, with the pro vi so that newl y-qua 1 i fi ed doctors might 
request samples of any medicinal products for a period of three years, 
irrespective of the date on which such products received market authorization 
(Amendment No. 59). Samples should also be such as to make it possible to 
administer at least on initial dose of treatment (Amendment No. 61). 
A majority was in favour of upholding the Commission's proposal to ban 
supplying to doctors samples of medicinal products containing psychotropic or 
narcotic substances within the meaning of international conventions. The 
rapporteur believes such a ban is necessary because: 
DOC_EN\RR\109301 
- 28 - PE 146.429/fin. 
the proposal already imposes a general restriction on the numbers of 
samples; 
doctors also need to familiarize themselves with such products; 
this group of products also includes relatively harmless ones such as cough 
syrups and 
all the Member States and the int~rnational conventions have strict rules 
on providing written evidence for the supply of such products, and this 
also applies to samples. 
Speci a 1 i st conferences and information meetings are an important forum for 
exchanging information on treatment and for acquiring additional knowledge. A 
large number of these conferences and events are financed or part-sponsored by 
the pharmaceuticals industry. This is to be welcomed per se since providing 
information on their products and also on the pathological causes of an 
illness is an important function of pharmaceuticals firms. 
By contrast, however, events at which the dissemination of scientific 
information merely takes second place to the social or tourist aspects are to 
be deplored. Although such forms of advertising are not called into question 
in other areas of the economy, thanks to our free economy, and a 1 though 
academically trained professionals may assume that their performance as 
doctors is unaffected by such activities, restrictions - intluding those of a 
legal nature - would seem justified and necessary, particularly in view of the 
special nature of medicinal products. However, such restrictions must not 
1 ead to a ban on appropriate sources of information where the se i ent i fi c 
nature is clearly predominant and where the financial sponsorship is known. 
Further training is an important opportunity for younger doctors and 
pharmacists to broaden and deepen their university training in the light of 
practical experience. 
The alternative to the funding of further training events by industry would be 
recourse to public spending or, possibly, fewer further training 
opportunities. In this respect the Committee endorsed the rapporteur's view, 
but insisted on proposing a new Article 9a (Amendment No. 57) to include the 
conditions under which pharmaceutical firms might organize congresses solely 
for the further scientific training of health care professionals. The 
Committee also called on the Commission to draw up a code of practice on the 
financing of such congresses. 
4. Monitoring of advertising 
To cover the special nature of pharmaceutical products, approval in principle 
of advertising involves comprehensive monitoring. The methods available vary 
from country to country in the Community and they can broadly be divided into 
three categories: 
a priori monitoring by the state (e.g. France); 
a priori monitoring by self-regulatory bodies (e.g. Britain); 
a posteriori monitoring by the state and/or self-regulatory bodies (e.g. 
in Germany). 
Comparisons between the nature of advertising permitted in the countries of 
the Community have shown that despite the differences in monitoring bodies 
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there are virtually no differences in practice. What this means is that the 
results of monitoring of medicinal products are similar and that no one system 
can be seen to be significantly better than any other one. In general the 
Commission proposal is based on this finding and it continues to permit 
different forms of monitoring which have proved their worth in the individual 
countries. This is to be welcomed. Monitoring of advertising should continue 
to be organized on a nation a 1 basis to permit an adequate assessment of the 
linguistic presentation of the advertising message. Contrary to the views of 
the rapporteur, the Committee - in Amendment No. 13 - was of the opinion that 
advertising of medicinal products should be the subject to preventive 
monitoring. 
5. Penalties 
The problem arises, by contrast, in the link between advertising measures and 
authorization in the context of the proposed penalties. There can be no doubt 
that substantial penalties are valuable, particularly in the case of 
persistent infringements of the directive. However, such penalties should be 
based on the advertising, for example in the form of a ban on advertising or a 
fine. This is covered by some of the amendments. Revoking authorization 
could, in the rapporteur's opinion, involve unacceptable consequences for 
patients if, for example, a vital product were no longer available for a 
specific period because there was something wrong with the advertising. There 
is the risk that innocent consumers could suffer from such a measure. 
Furthermore, existing penalties have proved effective at the national level. 
There is no evidence of persistent infringements of laws on advertising. 
,6. Conclusion 
These theoretical considerations justify the amendments proposed by 
Parliament. Subject to adoption of these amendments, the European Parliament 
supports the Commission's proposal because on the whole it is well-balanced. 
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ANNEXE 
~GLEMENTATIONS NATIONALES CONCERNAUT L'INFORMATION ET LA PUBLICITE 
)ESTINEE AUX PROFESSIONS De SANTE 
INFORMATION 
MEDICALE 
Monographies 
Oictionnaires 
non-officiels 
PUBUCITE 
MEDICALE 
CODES 
VOLONTAIRES 
D'-ErnlOUE 
-ECHAHTIU.ONS 
MEOICAUX 
0 00 
0~ 
Conformes a la D.-E. 83/570/CEE1 Art. 4bis 
Conformes a la section 11 a de la 2e Lol de Retorme de 
la Loi sur tes Medicaments du 16/08/86, odatees. 
la "Rote Usta" regroupe les monographies des medica· 
ments fabriques indu-striellement par les laboratoires-
membr,as du BPl, cetta liste a una tres grande notoriete et 
se trouve chez tous les medecins. 
Lol dans le Domaine de la Publicite du 11/07/651 
amend ea fa 18/10/75 et Code d'ethique. 
t() I 
Conforme a I' AM M, .elfe doit indure: 
composition du produit {designation .et quantite des princi-
pes actifs), Indications, contre-indications, effets secon· 
daires et mises en garde. 
PAS OE CONTROLE A PRIORI. 
Controle a posteriori par des comites de controle des 
L.ander et par des associations d'autodiscipline. 
Code d'autodiscipfina odu Sundesver-band der 
Pharmazeutischen Industria (BPI). 
Code AIM. ")~ 
Lol sur les Medicaments amendee en 1978 et 19861 
sect.47 {3 et 4). Foumis sur demande du medecin, en 
quantites limitees, marques: ·emantillon, ne peut etre 
vendu•. Trace de leur distribution doit etre gardee. 
·- - 0 ••• - --· 0 --
1 1 A.M.M. : Autorisation de Mise sur le March~ 
* 2 Code F.I.I.M. : codex de la F~deration Internationale de l'Industrie 
du M~dicamen 
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INFORMATION 
MEDICALE 
Monographies 
Dictionnaires 
non-offtciels 
officiel 
PUBUCiiE 
r~.,:EOICALE 
cooes 
VQLONTAIRES 
o"E.nUOUE 
-ECHANTILLONS 
MEDICAUX 
, •c-."'W. 
. , ,., .. ,. 
. ., ...... f 
···~':: 
- ...... 
Conformes a la O • .e. 83/570/CEE, Art. 4bfs 
Conformes An'ete Royal du 03/07/1969. 
>-)3 
·compendium• de f'AGIM .. publ&e annueUement. 
•Medex• information breve, trimestrielle 
"Repertoire commente des Medicaments" publh3 par le 
Ministers de la Sante. 
Arrete Royal du 09/07/1984 et Code d'ethtque. 
Conforms a l'AMM. 
La personne responsabf~ (med.ecin ou pharmacien agree 
' 
par le Ministere de la Sante) de !'information pharma- · 
ceutique pour tout fabricant ou importateur doit verifLer la 1 
conformite avec les lois et reglementations sur !'information 1 
et la pubfiCite. En -cas de non resoect des principes 
ethiques ou lega~ -cette personne .peut etre revoauee. 
PAS DE CONTROLE A PR-tORI. 
Contr61e a posteriori par le Ministere non systematique. 
Code de Conduite de I'AGIM/AVIGI 
Code FilM 
Regis par A-rretes Royaux du 01/12/76, 25/03/77, 
04/05/78 et 02/06/iB. lis doivent ~tre enregistres et sont 
assujettis aux memes regles que les conditionnements 
normaux:. 
* 3 A.G.I.M. : Association G~n~rale de l'Industrie du M~dicamen 
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INfORMATION 
MEDICALE 
Monographies Conformes a la D.E. 83/570/CEE. Art. 4bts 
Dictionnaire ·Laegamlddelkataloget" 
non--officiel 
i Puaucrre Lol su~ les Medicaments, N • 327 du 26/06/75, Art. 31 
MEOtCALE et Code d'Ethfque 
Conforme a l'AMM 
I 
I 
I Publicite au(XeS des medecins, pharmaciens, dentistes, 
veterjoaires et etudiants. 
<~~)'I 
Publicite conforme au RCP. y compris le prix du produit, 
r~mbQursement, ~ndttigos SQ~~ial~s Q~ Qi~tribution. 
tmprimes dates. 
Publicites de rapper abregees. i 
PAS DE CONTROL€ A PRIORI. 
Un comtte d'autoreglementation rec;oit un exemplaire au I 
moment de la distribution de la publicite, s'il trouve matiere : 
a -objection, il regie l'affaire avec la firme, sans faire I I 
intervenir les autorites. I 
Possibilite pour le Ministere de la Sante d'exiger des 
cor-rections ou additions pour una publicite, dent il pourra 
definir la forme et le contenu. 
COD-ES Code de Pratiques MEFA*/MEOIF·, 
VOLONTAIRES Comites de contr6te indep. nommes par MEFA et MEDIF. I D'Ern!OUE Code FilM. 
ECHANTILLONS Regis par Notification N· 411 du 14/08/85. Fournis aux I 
MEDICAUX medecins, dentistes ou veterinaires, dans le plus petit I 
conditionnement, un par medecin, durant la premiere 
annee de mise sur le marche au Danemark. Marques: 
•echantillon gratuit". 
" MEFA : Association de l'lndustrie Pharmaceutlque Danoise 
" MEDIF: Association des lmportateurs de S~cialltes Pharmaceutiques 
• 
1
• R.C.fJ.: f~t,qlSfr'Y of Comparative Pathology 
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INFORMATION 
M~DICALE 
Monographies 
Dictionnaire 
non-officiel 
PUBUCITE 
MEDlCALE 
CODES 
VOLONTAIRES 
D'ETHIOUE 
ECHANTIU.ONS 
MEOICAUX: 
Conformes a la O.E. 83/570/CEE, Art. 4b{s 
"Vademecum rnterna.cfona(• contenant resumes etc. 
Informations pourront etre homologuees, le cas echeant, 
par Ministere de la Sante. 
Decret de la Couronne N· 3451 du 1/12/77, 
section 29 et Code d'ethique 
Conforme a f'AMM 
PAS DE CONTROLE A PRIORI pour la publiclte dans la 
presse professionnelle. 
Code FilM adopts par la FARMAINOUSTRIA. 
Decret de la Couronne N • 3451 du 1/12/77. 
foumis aux medecins sur demande prealable, durant deux 
ans suivant I'AMM. Conditionnements commerciaux, 
marques •8chantmon•. 
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IN FORMA TlON 
MEDICALE 
Monographies 
Dlctionnaire 
offlciel 
PUBUCITE 
MEDtCALE 
CODES 
VOLONTAlRES 
O'ElliiQUE 
ECHANlllLONS 
MEDtCAUX 
Conformes a la O.E. 83/570/CEE, Art. 4bfs 
Conformes a I"AMM (Annexe 1), regulierement mises a 
jour. 
Vkfal, monographies approuvees par le Minlstere de la 
Sante et actuafisees. 
Decret du 23/09/19871 N• 87-772, J.O. 24/09/87. 
Conforme au RCP et aux mentions exigees par la legis-
lation sur les prix et la j6oisfation sociale. 
PAS OECONTROLE A PRIORI. 
Le -pharmaden responsab!~ en matiere d'information et de 
publicite dolt verifier la conformite des elements 
pubticitaires proposes aux professlonnels de la sante. En 
cas de litiges, il devra defendre son dOssier devant la 
Commission pleniere de Publicite, nommee par le 
Ministere de la Sante. 
La pubticite sera deposee des sa diffusion aupres des 
autorites, versement d'une redevance. 
Contr<>le a posteriori par une Commission du Ministere de 
la Santa non systematlque. 
Code Commun d'Ethique de I'Ordre National des 
Pham'laciens, de la Section Medicate de !'Union des 
Annonveurs et du S.N.I.?~'"J 
Code 'FilM. 
Article R .. SQ4S.2 
Peuvent etre remis aux medecins et sous certaines 
conditions aux dentistes et sage-femmes pendant toute la 
duree de la commercialisation. 
Delivrance interdite dans les enceintes accessibles au 
public lors de congres. 
Conformes aux conditionnements commercialises et 
marques ·Echantillon medical gratuit". 
* 5 S.N.I.P. Syndicat National de l'Industrie Pharmaceutique 
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INFORMATION 
MEDICALE 
Monographies 
Dictionnaira 
non-offtciel 
PUBUCITE 
MEDICAl-€ 
Conformes a la D.E. 83/570/CEE, Art. 4bls 
Conformes a •Medicines Act 1968, The Medlclnes (Data 
Sheet) Regulations 1972 •• 
Conformes a l"AMM 
•ABPI~ata Sheet Compendium·, .publie regullerement 
•Medicines (Advertlsing -to Medical and Dental 
Practltfoners} Regulation 1978 (S1197St et Code 
d'ethique. 
la publicite aupies du medecin doit s'accompagner de la , 
remise ou de l'enyoi de la mooooraphie. Publicites con-
formes aux detat1s du ·eode of Practice for the Pharma-
ceutical Industry• et les ·AdvertiSing Regulations•. 
Tout materiel promotionnel imprime doit etre certifie 
.conforme par deux personnes responsables pour le fabri-
cant, dent un est medecin. Leurs noms sent notifies par 
avance aux autorites d'enregistrement. 
PAS DE CONTROLE A PRIORI. 
le •Code of Practice Committee" contro!e les pubfiCites 
pour s'assurer de leur conformite avec I'AMM et la 
monographia et publie regulierement un rapport d'activite. 
CODES Code de Pratiques de I'ABPI. 
VOlONTAIRES Code FilM. 
O''ETHIOUE 
€CHANTILlONS Le ·code of Practice -for the Pharmaceutical Industry" 
MEDICAUX regit la distribution des echantillons. Us ne devront etre 
donnes aux medecins que sur demande signee. Les 
firmes pourront fournir au msdecin des cartes de demande 
pre-imprimees. Cette carte ne s'applique pas aux produits 
soumis au MMisuse of Drugs Act de 1971·. Un echantillon 
individuel ne devrait pas repn§senter plus de 4 jours de 
traitement pour un seul patient 
* 6 A.B.P.l. : Association of the British Pharmaceutical Industry 
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INfORMA llON 
MEDICAte 
Monographtes Conformes ala D.E. 83/570/CEE, A~. 4bts 
Conformes a l'AMM ! 
PUBUCITE Conforme au RCP. 
MEDICAtE 
Besponsable de pubftcite pour ohaque laboratoire signe les 
documents, gardes 3 ans. Date, code produit, numero de 
serie. La responsabilite pour la presentation et le contenu 
de la publicite reste a la ftrme. 
PAS DE CONTROLE A PRIOR[. 
Depot pr€alable a I'E.O.F. (National Drug Organisation) qui 
0 peut exiger la correction ou le retrait d'une publicite parue I 
si elle n'est pas conforme ou si elle est trompeuse. I J 
CODES Code de Conduite de I' Association des fabricants ! 
VOLONTAJRES Pharrnaceutiques. I o'ETHIOUE Code FilM 
ECHAt4TtU..ONS la distribution d'echantillons mooicaux aux medecins n'est ! 
MEDtCAUX pas autorisee. 
-·· 
..... _ 
.. ..... 
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(N·FORMATION 
MEDICALE 
Monographies 
Dictionnaire 
non-offiCiel 
PUSUCITE 
MEOlCAt.E 
CODES 
VOLONTAIRES 
O'"ETHlQUE 
·ECHANTILLONS 
MEOICAUX 
Conformes a la D.E. 83/570/CEE, Art. 4bis 
Conformes a I'AMM. 
·Irish Data Sheet Compendium•, publie regulierement 
par la Federation de l'lndustrie (FICI). 
Ucencing, Advertlslng and Sales Regulations de 1984 
{Sl N • 210) et Cod a de condulte. 
PAS DE CONTROLE A PRIORI. 
Pas de depot prealable. 
Code of Marketing Practice for the Pharmaceutical 
Industry• de la -Federation of Irish Chemical Industries 
(FICI), controls .par un -comite nomme par la Div. Pharm. 
de la -Federation. 
Code FilM. 
Le Code de Pratfques definit leur distribution. Pas -de 
restrictions legates, mafs la ·cir-culation d'echantillons non 
sollicites est decouragee. 
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INFORMATION 
MEDICAt..E 
Monographies 
Dictionnaires 
non off!Ciel 
officiel 
PUBUCITE 
MEDICALE 
CODES 
VOLONTAIRES 
D''ETHIOUE 
i :ECHANTILLDNS 
M€DICAUX 
Conformes a fa D.E. 83/570/CEE, Art. 4bis 
Conformes a l'AMM. 
"Prontuario" reactualise et publie regulierement. 
"lnformatora Farmaeeutfco• 
Clrculaires D.M. 23/06/81 1 D.M. 23/11/82, D.M. 
26/02/65. 
Un RCP -doit accompagner le materiel promotionnel. 
L'accent doit etre mis sur les centre-indications, les mises 
en garde .et les effets indesirables. 
Le nom generique du medicament doit egalement 
apparrurre dans la publicite. 
:ENVOI 45 JOURS AV ANT 'PUBLICATION, au Ministers de 
la Santa, de touts publicite. La regie de •silence vaut 
accord tacite" s·applique. 
Code d'Ethique de la FARMINDUSTRIA obligatoire. 
Un Comite de Controle statuera sur les infractions 
eventuelles. 
Code FilM. 
Decret Mlnisteriel 23/06/81 et D.M. 23/11/82. 
lis peuvent etre remis gratuitement aux medecins pendant 
les 2 premieres imnees suivant le lancement du produit. 
Apres deux ans, ils peuvent etre obtenus sur demande 
ecrite. Marques: MEchantillon medical, ne peut ~tre vendu". I 
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INFORMATION 
MEOICALE 
Monographies 
Dictionnaire 
non-offiCiel 
PUe<JCtT-E 
M€OICALE 
CODES 
VOLONTAIRES . 
o'Enuoue 
ECHAN11l.LONS 
MEOICAUX 
Conformes a la D.E. 83/570/CEE, Art. 4bls 
Conformes a l'AMM 
•Repertorlum• qui regroupe les monographles et qui est 
actualise et pubUe regulierement. 
L'information et la publicite doivent au moins comporter les 
elements suivants, conformes a I'AMM: 
- nom du produit 
- composition qualitative et quantitative des principes actJfs, 
- -forma pharmaceutique, 
- principales indications, 
- principaux effets secondaires, 
• toutes les centre-indications. 
! 
11 y a allegement pour la publicite de rapper. 
ta promotion pour les indications autres que celfes 
enregistrees ou pour des usages qui ne sont pas 
directement lies au champ d'indications enregistrees, n'est 
pas permise. Pas de publicite comparative. 
PAS DE CONTROLE A PRIORI 
Code de Conduite Neerlandais, edite par NEFARMA, 
contient dans son integraUte le Code FilM. 
Le Gonseil-de la Promotion des Medicaments contrOie et 
applique ce Code et intervient en cas de plaintes. 
Reglementatlon de fevrfer 1980. les echantillons 
.gratuits sent autorises pendant les 2 ans suivant la date 
. d'AMM, seu{ement deux paquets du plus petit 
conditionnement commer-cialise et uniquement aux 
medecins. Obligation de garder trace de la distribution. 
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INfORMAnON 
MEDICALE 
Monographies 
Dictionnaires 
non-officiels 
Pusucn'E 
MEOlCALE 
COOES 
VOLONTAIRES 
O'ETHIOUE 
ECHANTILLONS 
MEOICAUX 
Conformes a la D.E. 63/570/CF.E, Art. 4bts 
Conformes a l'AMM 
•stmposlum Terapeutico• et •tndice Nacional 
Terapeutlco, edites tous les ans. 
Decret t57/88, du 19/06/88, N• 1. 
Con forme au RCP. 
la publicite doit .expressement comprendre: 
··nom generique ·joint au nom de marque du produit, 
- coOt journalier du traitement, 
- prix de vente au public, 
- remboursement. 
PAS DE CONTROL-E A PRIOR(. 
Contr6te a posteriori .effectue par la Direction Generale des 
Affaires Pharmaceutiques (OGAF). 
Code de P.ratiques APtFARMA, base sur le Code fUM. 
Distribution uniquement aux mooecins. Pas de limite dans 
la quantite et ie temps de distribution. L'echantillon peut ne 
f28S ~tre identiou~ (en contenance) au modele-vente; ceci 
est de la responsabilite du laboratoire. 
---------------------------
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OPINION 
{Rule 120 of the Rules of Procedure) 
of the Committee on Economic and Monetary Affairs and Industrial Policy 
for the Committee on the Environment, Public Health and Consumer Protection 
Draftsman: Mr 01 RUPO 
At its meeting of 16 October 1990, the Committee on Economic and Monetary 
Affairs and Industrial Policy appointed Mr 01 RUPO draftsman. 
At its meetings of 18-20 December 1990 and 5-7 February 1991, it considered 
the draft opinion. 
At the 1 atter meeting it adopted severa 1 
directive; voting 21 in favour and 21 
conclusions as a whole. 
amendments to the proposal for a 
against, it did not adopt the 
The following took part in the vote: Beumer, chairman; Desmond, vice-chairman; 
Fuchs, vice-chairman; di Rupo, rapporteur; Barton, Beazley, Bernard Reymond, 
Bofill Abeilhe, Cassidy, Caudron, Cox, de Donnea, Donnelly, Friedrich, Herman, 
Hoff, Lataillade, Mattina, Metten, Merz, Patterson, Pinxten, Read, 
Ferreira Ribeiro, Rogalla, Roumeliotis, Seal, Siso Cruellas, Tongue, 
von Wogau, Wettig, Braun-Moser {for Gallenzi}, Daly (for Steven}, David (for 
Christiansen}, Fitzgerald (for Ruiz Mateos}, Nielsen (for Visentini}, Peijs 
(for Sboarina}, van Hemeldonck (for Mihr} and Arias, Green, Sarlis and Zavvos 
pursuant to Rule 111. 
opc..:._EN\RR\109301 
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I. THE ECONOMIC IMPORTANCE OF THE PHARMACEUTICAlS SECTOR 
The twelve Member States of the European Community together comprise one third 
of the world market in pharmaceuticals. The United States' share is roughly 
equivalent, while Japan accounts for some 18% of the market. 
Europe's balance of trade in medicinal products has been in surplus since the 
beginning of the 1980s (with an annual growth rate of 4.6% from 1980 to 
1987), doubling in 8 years to reach a balance of trade surplus with the rest 
of the world of over 3.8 billion ECU. 
The pharmaceutical companies' turnover on the European market more than 
doubled between 1980 and 1988, rising from 19 bn to 46 bn ECU. 
As regards employment, the pharmaceutical industry provided jobs for almost 
450 000 people inside the European Community in 1989, of whom over 10% worked 
in the research sector. A further 1.2 m people are employed in jobs generated 
indirectly by the industry. 
Products for self-medication account for almost 30% of the total market in the 
United States. In Europe, on the other hand, they currently represent only 
15% of the market. Specialists forecast, however, that products for 
self-medication will eventually account for 30% of the Community market also. 
11. PROS AND CONS OF THE PROPOSAl 
1. Need for Community rules on the advertising of pharmaceutical products 
All the Member States apply regulations concerning the advertising of 
pharmaceut i ea l s. Yet those regulations vary from one Member State to 
another, part i cul arl y with regard to advertising to the general public. 
All the Member States prohibit the advertising of prescription-only 
products, but certain states (such as Belgium and Denmark) prohibit any 
radio or television advertising of pharmaceutical products, or any 
advertising of such products to the general public whatsoever (Greece). 
The standards for and constraints on advertising of pharmaceut i ea l s vary 
from one Member State to another. Similarly, the advertising of 
pharmaceuticals is subject either to retrospective regulation by the 
courts (as in Germany and Bel g i urn) or to prior monitoring, either by a 
public regulatory body (as in France, Spain, Italy, Denmark, Portugal and 
Luxembourg) or by the industry's own self-regulatory bodies (as in the 
United Kingdom, Ireland and the Netherlands). 
Furthermore, certain medicinal products require a med i ea l prescription in 
some Member States, but not in others while in certain Member States the 
cost of products that do not require a prescription may still be 
reimbursed if obtained on prescription. These conflicting rules are 
liable to impede the free movement of medicinal products. 
DOC_EN\RR\109301 
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It is also necessary to secure freedom to 
si nee in future advertising campaigns for 
several Member States at the same time. 
market will require common rules for the 
with regard to both consumer protection and 
provide advertising services, 
medicinal products will cover 
The completion of the single 
advertising of pharmaceut i ea l s 
the marketing of products. 
The Commission proposal does, therefore, meet a need, although it needs to 
be tightened up. 
2. The relatively neutral effect of the proposal 
It is, admittedly, difficult to establish with certainty the extent of 
pharmaceuticals advertising. It accounts for significantly more than the 
12 to 15% of pharmaceut i ea 1 companies' turnover suggested by the 
Commission and, as the manufacturers' themselves admit, may account for up 
to 30% of their turnover, compared to a figure of some 15% of turnover for 
research and development costs. 
The marked rise in expenditure on advertising and marketing in general 
reflects the companies' need to recuperate the very high development costs 
of such products as swiftly as possible, but also growing competition 
between pharmaceutical firms as the industry becomes increasingly 
concentrated. 
The Commission's proposal appears to be relatively stringent. In 
practice, however, it seeks a middle way between the various national 
regulations currently in force and opts for a more fl exi bl e system than 
that now applied in some Member States. In so doing, the proposed 
Community legislation reflects a relatively neutral approach to the 
advertising of pharmaceuticals to the general public, and one wonders 
whether this is advisable. Should we encourage the constant rise in the 
pharmaceutical industry's expenditure on advertising {currently double 
their research budgets}? On the contrary, there are many reasons for 
seeking to reduce that expenditure. 
In the case of OPREN {or BENOXAPROFEM} for example, an anti-arthritis drug 
produced by Ell LILLY, the aggressive advertising campaign for the product 
included a three-day cruise on the Rhine for a number of prominent 
rheumatologists. 
This campaign, which seems to have cost more than the product's 
developments costs, cost the British National Health Service £13.5 mn. 
It appears that this product caused about 100 deaths and made a further 
1500 people 111 3 • 
In 1988, in the United Kingdom, it 
pharmaceutical industry spent 80 times 
Service on information to doctors. 
was demonstrated that the 
more than the National Health 
3 Journal of Consumer Policy 12, pp. 397-414, 1989 
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Should we leave responsibility for informing the general public and 
medical practitioners to the manufacturers alone? Would it not be better 
to compel all the Member States to ensure that neutral and objective 
sources of information existed in their countries? Such arrangements 
should, in particular, enable medical practitioners to obtain 
comprehensive and accurate information about all medicinal products. 
Is one much-hyped product really more effective than another? What new 
health benefits does it offer? 
In addition to providing for neutral and objective sources of information 
at national level, the Commission should set up a European data bank on 
medicinal products. It appears that such a data bank is currently being 
considered, particularly in the context of Directive 89/105/EEC on price 
transparency for medicinal products. The process of setting up this data 
bank should be accelerated and it should comprise not only data on the 
price of medicinal products but also all the data contained in their 
accompany; ng 1 eafl ets and any other information of interest to doctors. 
This data bank should be funded by the pharmaceutical manufacturers 
accessible to every doctor in the Community either by telephone or, 
eventually, by computer. 
When it comes to advertising to the general public, as the BEUC (European 
Bureau of Consumers' Unions) has emphasized, radio and television would 
not appear to be appropriate media for the promotion of products for 
self-medication. On the contrary. The brevity of radio or TV commercials 
and the over-simplified and emotional messages they contain make it 
impossible to convey the basic information needed by consumers. It is 
clearly necessary to prohibit all radio or TV advertising of medicinal 
products. 
Furthermore, some countries have very restrictive policies concerning the 
advertising of medicinal products. The directive should take that into 
account and allow Member States to apply more restrictive rules if they 
wish. 
Genera 1 expenditure on marketing to practitioners increases the cost of 
medicinal products and, albeit insidiously, tends to make the medical 
profession dependent on the pharmaceutical companies. Finally, 
advertising campaigns do not necessarily boost sales in general, but 
increase sales of certain new products to the detriment of older, but 
often equally effective, products. 
The directive does not pay sufficient attention to the role of medical 
sales representatives. The major international pharmaceutical companies 
increased the number of such sales representatives by 50% between 1983 and 
1988, and they play a crucial role in influencing doctor's decisions. 
According to the 'Economist' of 27 January 1990, six out of ten doctors 
stated that they had prescribed medicinal products solely on the basis of 
information provided by medical sales representatives. 
DOC_EN\RR\109301 
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It is necessary, therefore, to ensure that these representatives receive 
adequate training and are answerable, within their own company, to a 
medical practitioner. Doctors should have a means of obtaining redress if 
they are given inaccurate information by medical sales representatives. 
While there should be extremely stringent rules on the subject of 
information for doctors, the provision of purely scientific information by 
the pharmaceutical industry should, perhaps, be allowed. It should, 
however, be carefully controlled and should not simply amount to promoting 
the prescription or sale of a product. 
3. Lack of effective regulation 
The proposal is not only relatively neutral concerning the advertising of 
pharmaceutical products, but also fails to ensure that the implementation 
of its own provisions are monitored effectively. 
The proposal should not simply specify obligations; it should also provide 
for compliance with such obligations to be monitored and penalties 
imposed. 
Yet the proposal leaves the task of monitoring the implementation of 
Community rules to the Member States, which are required to 'ensure that 
there are adequate and effective methods to monitor advertising of 
medicinal products'. These methods may be very diverse, ranging from 
preliminary or retrospective monitoring by national authorities to self-
regulation by the pharmaceutical industry; the Commission does not come 
down in favour of any particular option. This is liable to produce 
variations in implementation which could be detrimental to health 
objectives and lead to distortions of competition. 
Given these vague provisions for regulation by the Member States, it seems 
unlikely that the industry will comply fully with certain obligations 
contained in the directive (for example, in relation to free samples for 
doctors, the requirement that firms should issue no more than two samples 
per year to each doctor, and only in response to a written request). 
The proposed sanctions, also, are not particularly convincing. Fines 
imposed by courts are often insignificant in relation to the size of the 
companies in question, while the provisions of Article 13 appear to be 
inappropriate and their application is, in any event, left to the 
discretion of the Member States. 
4. Need for Community regulations concerning para-pharmaceutical products 
The directive does not cover para-pharmaceutical products (such as 
vitamins, dietary products, sun-protection products, etc.), as it is 
concerned solely with medicinal products proper. However, though on the 
border-1 i ne such products are marketed in such a way as to create the 
illusion that they possess medicinal properties. Yet they are excluded 
from all the regulations applied to medicinal products. The Commission 
should, therefore, also introduce legislation on the advertising of and 
claims made for para-pharmaceutical products to bring them within the 
DOC_EN\RR\109301 
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scope of similar rules to those applied to medicinal products for human use, 
si nee such products are often presented as having a beneficia 1 effect on 
individuals' health or well-being. 
DOC_EN\RR\109301 
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The Committee on Economic and Monetary Affairs and Industrial Policy calls on 
the Committee on the Environment, Public Health and Consumer Protection, as 
the committee responsible, to incorporate the following amendments in its 
report: 
Commission text 
2. For the purposes 
Directive 
(Amendment No. 1) 
New recital 2a 
Amendments 
Whereas the advertising to the 
public of non-prescription medicinal 
products is an important element in 
the information of patients. In 
particular, it informs consumers of 
the methods of treating minor 
ailments themselves; 
(Amendment No. 2) 
New recital lOa 
Whereas in applying this Directive 
Member Stats should ensure that its 
provisions apply to all parties who 
may influence prescribing habits; 
(Amendment No. 3) 
Article 1(2), first indent 
of this 2. For the purposes of this 
Directive, 
-the definition of 'advertising' 
shall be that laid down in 
Article 2 of Directive 
84/450/EEC, 
- the definition of 'advertising' 
shall be that laid down in 
Article 2 of Directive 
84/ 450/EEC. Information of a 
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purely, scientific, technical 
or educational nature shall not 
be considered as 'advertising' 
in the sense of this Directive, 
PE 146.429/fin. 
Commission text Amendments 
(Amendment No. 4) 
Article 1(3), third indent 
- any incitement 
supply medicinal 
gift, offer or 
benefit or bonus, 
to prescribe or 
products by the 
promise of any 
whether in money 
or in kind, including invitations 
to travel or to congresses, 
any incitement to prescribe or 
supply medicinal products by the 
gift, offer or promise of any 
benefit or bonus, whether in 
money or in kind, i ne 1 ud i ng 
invitations to travel or to 
congresses, except when these are 
of a purely scientific nature. 
(Amendment No. 5) 
Article 3(1) and (5) 
1. Member States shall prohibit the 
advertising to the genera 1 pub 1 i c 
of: 
- medicinal products which contain 
psychotropic or narcotic 
substances, within the meaning of 
the international conventions, 
- other medicinal products which are 
only available on medical 
prescription, in accordance with 
touncil Directive .. / ... EEC. 
5. Member States shall prohibit the 
free distribution of medicinal 
product$ to the public for 
prqmot ion a 1 purposes. 
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1. Member States shall prohibit the 
advertising to the general public 
of: 
medicinal products which contain 
psychotropic or narcotic 
substances, within the meaning of 
the international conventions, 
medicinal products and doping 
agents, as defined by the Council 
of Europe and the International 
Olympic Committee, that give rise 
to addictions and/or dependence, 
medicinal products and doping 
agents, as defined by the Council 
of Europe and the International 
Olympic Committee, that give rise 
to addictions and/or dependence, 
other medicinal products which 
are only available on medical 
prescription, in accordance with 
Council Directive .. / ... EEC. 
Member States shall prohibit the 
unsolicited distribution of 
medicinal products to the public 
for promotional purposes 
PE 146.429/fin. 
Commission text Amendments 
(Amendment No. 6} 
Article 4(b} 
(b) include the following minimum 
information: 
- the name of the medicinal 
product incorporating or 
followed by the common name if 
the medicinal product contains 
only one active ingredient, 
- the information necessary for 
correct usage of the medicinal 
product, such as indications for 
use and special precautions, or, 
failing this, an express 
invitation to read the package 
leaflet carefully. 
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(b) include the following minimum 
information: 
- the name of the medicinal 
product, 
- the information necessary for 
correct usage of the 
medicinal product, i.e. its 
areas of application and an 
express invitation to read 
the package leaflet 
carefully. The advertising 
of a medicinal product to the 
public may, notwithstanding 
the above, i ne 1 ude on 1 y the 
name of the medicinal 
product, if its sole object 
is to draw attention to the 
latter, 
all contra-indications, the 
principal side-effects or adverse 
reactions·, appropriate 
precautions for use, possible 
interaction with other substances 
and any other special 
recommendations, 
an invitation to ask the doctor 
or pharmacist about risks and 
side-effects. 
PE 146.429/fin. 
Commission text Amendments 
(Amendment No. 7) 
Article 6(1) 
1. Any advertising of 
product to persons 
prescribe or supply 
shall include: 
a medicinal 
qual ifi ed to 
such products 
the particulars listed in the 
summary of product 
characteristics, 
the legal prescription status of 
the medicinal product, 
the retail price of the various 
presentations, 
if appropriate, conditions of 
coverage by the social security 
systems. 
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1. Any advertising of a medicinal 
product to persons qualified to 
prescribe or supply such 
products shall include: 
the particulars listed in the 
summary of product 
characteristics, 
the legal prescription status of 
the medicinal product when this 
has been agreed at Community 
level , 
Deleted 
Deleted 
- persons qualified to prescribe or 
supply medicinal products should 
receive information on the retail 
price of the various presentations 
and, if appropriate, the 
conditions of coverage by the 
social security systems in 
accordance with national 
provisions. 
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Commission text Amendments 
(Amendment No. 8) 
Article 9(1) and (2) 
1. In the course of promoting 
medicinal products to persons 
qualified to prescribe them, it shall 
be prohibited to give, proffer or 
promise to such persons, directly or 
indirectly, any gifts, pecuniary 
advantages or benefits in kind with 
the exception of objects of an 
insignificant intrinsic value. 
2. Persons qualified to prescribe or 
supply medicinal products shall not 
solicit or accept any inducement 
prohibited under paragraph 1. 
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1. In the course of promoting 
medicinal products to persons 
qualified to prescribe them, it 
shall be prohibited to give, proffer 
or promise to such persons, directly 
or indirectly, any gifts, pecuniary 
advantages or benefits in kind with 
the exception of objects of an 
insignificant intrinsic value. 
Notwithstanding the above, it shall 
be permitted for assistance to be 
provided to health-care 
professionals to attend congresses 
and other meetings of scientific 
interest provided all such 
assistance and hospitality is 
reasonable. 
2. As an exception to the provisions 
of paragraph 1, it shall be 
permissible to finance medical 
studies and conferences provided 
that the existence of such funding 
is clearly established beforehand, 
and the identity of the person 
providing the funds is revealed. 
any documents relating to the 
studies or conferences in question 
must mention the existence of a 
source of outside funding and the 
identity of the party supplying 
those funds. 
PE 146.429/fin. 
Commission text Amendments 
(Amendment No. 9) 
Article IO(a) to (c) 
a) two samples at the most may be 
provided every year to any person 
qualified to prescribe or to supply 
medicinal products; 
.Q) any supply of samples must be in 
response to a written request, signed 
and dated, of the recipient; 
~) the samples shall be identical to 
the smallest presentation on the 
market; 
Deleted 
~) any supply of samples must be in 
response to a written request, 
signed and dated, of the recipient; 
.Q) the samples shall be of a size 
which is reasonable in relation to 
the product's actual use; 
(Amendment No. 10) 
Article 11(1) 
1. Member States shall ensure that 
there are adequate and effective 
methods to monitor advertising of 
medicinal products. Such methods 
shall incl~:~de legal provisions 
under which persons or 
organizations regarded under 
national law as having a 
legitimate interest in prohibiting 
any advertisement inconsistent 
with this Directive may take legal 
action against such advertisement, 
or bring such advertisement before 
an administrative authority 
competent either to decide on 
complaints or to initiate 
appropriate legal proceedings. 
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1. Member States shall ensure that 
there are adequate and effective 
methods to monitor advertising of 
medicinal products. Such methods 
shall include legal provisions 
under which persons or 
organizations reg,arded under 
national law as having a 
legitimate interest in 
prohibiting any advertisement 
inconsistent with this Directive 
may take legal action against 
such advertisement, or bring such 
advertisement before an 
administrative authority 
competent either to decide on 
complaints or to initiate 
appropriate legal proceedings; 
Member States shall encourage 
producers to adopt a system of 
voluntary control of advertising 
of medicinal products by 
recourse to self-regulatory codes 
with effective organs of control. 
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la. The judicial or administrative 
proceedings referred to in 
~agraph 1 should always be 
available in the event that 
voluntary control of advertising of 
medicinal products by self-
regulatory bodies, or recourse to 
such bodies, proves inadequate. 
(Amendment No. 11) 
Article 12, paragraph 2, first indent 
make available to the bodies 
responsible for monitoring 
advertising of medicinal products 
a sample of all advertisements 
emanating from their undertaking 
together with a statement 
indicating the persons to whom it 
is addressed, the method of 
dissemination and the date of 
first dissemination; 
- retain at the disposal of the 
bodies responsible for monitoring 
advertising of medicinal products 
a sample of all advertisements 
emanating from their undertaking 
together with a statement 
indicating the persons to whom it 
is addressed, the method of 
dissemination and the date of 
first dissemination; 
(Amendment No. 12) 
Article 13(1) 
1. Where the provisions of this 
Directive have not been observed, and 
a warning notice served on the party 
concerned has remained without 
effect, the competent authorities of 
a Member State may suspend the 
authorization to market the medicinal 
product concerned, without prejudice 
to any other sanction which may be 
applied under national law. 
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1. Where the provisions of this 
Directive have not been observed, 
and a warning notice served on the 
party concerned has remained without 
effect, the competent authorities of 
a Member State may impose any 
sanction which may be applied under 
national law. Decisions concerning 
the suspension or revocation of 
marketing authorizations may be made 
on 1 y within the terms of Directive 
65/65/EEC. 
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